← All trials
NCT00223080
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2003
- Primary completion
- Jul 1, 2006
- Completion date
- Jun 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 16402
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- United States ArmyLead sponsor
- VaxGenCollaborator
- The EMMES CorporationCollaborator
- Mahidol UniversityCollaborator
- Henry M. Jackson Foundation for the Advancement of Military MedicineCollaborator
- Sanofi-AventisCollaborator
- Royal Thai Army Medical DepartmentCollaborator
- Government of ThailandOverall official - principal investigator
- Government of ThailandCollaborator
- United States ArmyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.